Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global monkeypox treatment market is expected to reach a valuation of US$ 93.84 million in 2023 and is projected to grow to US$ 249 million by 2033, registering a CAGR of 10.25% during the forecast period. The demand for effective treatment, vaccination, and other rare disease therapeutics is anticipated to propel the growth of the global monkeypox therapeutics market during the forecast period.
There is presently no specific treatment or defined pharmaceutical for the disease, but symptomatic treatment is possible, and a rise in demand for pain and itch relief caused by boils and rashes is positively impacting the growth of the monkeypox treatment market. Moreover, the surge in products approvals is also projected to fuel the monkeypox treatment market during the forecast period.
Likewise, according to the United States Food and Drug Administration, on 9 August 2022, Bavarian Nordic, a completely integrated vaccine company concentrated on the development, manufacturing and commercialization of life-saving vaccines, declared that its Jynneos vaccine received the approval from United states food and drugs administration as an emergency drug for the treatment of growing monkeypox disease. This will help in the expansion of the market in the forecast period.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | US$ 93.84 million |
Anticipated Forecast Value (2033) | US$ 249 million |
Projected Growth Rate (2023 to 2033) | CAGR 10.25% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for Monkeypox treatment was worth US$ 64 million in 2018 while growing at a CAGR of 7.95 % during the historical period. The mounting demand for monkeypox treatment and increasing research for specific treatments for monkeypox led to vast opportunities which will aid in market expansion. Governments around the world are proactively investing in research and development for the development of effective drugs and vaccines to control the growing number of monkeypox cases.
On the other hand, various governments have started promoting genetic engineering for the development of vaccines and have also begun campaigns for spreading awareness about the potential disease cause and prevention. In addition, the rise in healthcare expenditure day by day for advances in the treatment of monkeypox disease will witness profitable growth prospects during the forecast period that will benefit the market in long term.
For instance, In North America and various European countries, approval of two vaccines and antiviral drugs for the treatment of monkeypox, previously used for smallpox treatment and eradication will lead to market expansion in the projected period. The live attenuated vaccine, Imvanex (in Europe) and Jynneos (in the USA) is developed by Bavarian Nordic. Likewise, smallpox shot ACAM2000 was developed by EMERGENT (Emergent BioSolutions). Considering the above-mentioned factors, product approvals and developments, the monkeypox treatment market is projected to reach US$ 249 million by 2033, with a CAGR of 10.25%.
Surging demand for timely vaccines and potential disease treatments is expected to drive the growth of the monkeypox treatment market during the forecast period. Active investments in the research and development of effective vaccines and drugs to manage disease spread and treat affected patients are driving the growth of this market. Additionally, the government is taking steps to facilitate drug development by utilizing genetic engineering tools in order to provide vaccination in the event that the virus evolves and impacts a massive portion of the populace.
On the other hand, genomic sequencing for the virus would unravel the specific infection-causing sequences, which could help in the early diagnosis of viral infection and the development of effective vaccines for the population at risk of infection in the forthcoming period. Also, increasing healthcare expenditures by the population are fuelling investments for the development of new vaccines, which will drive the global monkeypox treatment market during the projected period. Currently, tecovirimat is the treatment of choice for people treating monkeypox. This is expected to propel growth during the forecast period.
Likewise, EMA’s human medicines committee recommended an extension of the indication of the smallpox vaccine IMVANEX to protect people from monkeypox infection. IMVANEX was approved in 2013 but it has been considered a crucial vaccine because of the similarities between smallpox and monkeypox. Furthermore, increasing Research and development activities and the use of the smallpox vaccine as an off-label product for vaccination against monkeypox are anticipated to propel the market in the forecast period.
Side-effects related to drug use to restrain market expansion
The growing side effects related to the drugs used to treat monkeypox are anticipated to restrict the growth of the market. The dearth of awareness and knowledge of the disease about the supportive treatment and the slow approval rate of specific therapeutic treatment for monkeypox is the major factor expected to restrain the growth of this market.
North America expected to dominate the market with the maximum share
North America dominated the market with a revenue share of 40.5% in 2022. It is projected to possess around 48% market share by end of the forecast period while growing at a CAGR of 9.1%. Growth is attributed to the presence of many dominating players, coupled with numerous strategic initiatives undertaken by them. Also, the rise in disease prevalence and growing awareness among people regarding vaccination is estimated to propel the growth of the regional market. Additionally, favourable support from the government and higher research and development investments are expected to provide lucrative opportunities for market growth of monkeypox treatment in this region.
In addition, on 4 august 2022, the United States department of health and human services, announced the monkeypox outbreak as a public health emergency. Due to this, there is a surging demand for vaccines and better treatment for monkeypox. Also, the rising prevalence of monkeypox disease and the growing demand for vaccines and new treatment for monkeypox is projected to fuel the growth of the monkeypox treatment market in this region.
Similarly, the United States government included the ACAM2000 drug in its strategic stockpile for the treatment of monkeypox. However, it is not commercially available yet. Presently, Siga Technologies’ Tecovirimat (TPOXX) and Chimerix’s brincidofovir (TEMBEXA) are the only two FDA-approved drugs for smallpox that are generally recommended for the treatment of certain patients with monkeypox. These approvals will help in the expansion of the market in this region during the forecast period.
Asia Pacific market expected to reflect the fastest CAGR
Asia Pacific is projected to witness the fastest growth of 11% during the forecast period. The growing number of monkeypox infections and increasing research and development activities for developing prevention and therapeutic options are some of the primary factors fuelling market growth.
The rising prevalence of infection in Asia Pacific countries such as Singapore, Australia, and India is anticipated to propel market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
An oral segment to dominate the market with maximum share
In 2022, the oral segment held the largest market share of 65.0% and it is estimated to possess more than 70% share by end of the forecast period. Surging demand for oral route therapeutics, ease of administration, and cost-effectiveness of oral products are some factors contributing to the segment expansion.
Likewise, most common drugs such as tecovirimat and brincidofovir are administered orally which is expected to boost the growth of this segment during the forecast period.
Tecovirimat driving growth with a maximum share
This segment is estimated to account for 61% market share in the monkeypox treatment market by end of 2033. This drug is expected to grow with a CAGR of 11.2% during the forecast period. Growth is attributed to the accepted safety profile offered by Tecovirimat during clinical trials and for the treatment of monkeypox in severe cases.
This drug is also accepted as the first line of therapeutic treatment recommended by the United states food and drug administration (FDA). It is also approved in European countries as well. The validation provided by these bodies and promising results from clinical trials is driving the growth of this segment. Moreover, ‘Tecovirimat’ is proven to be the only effective drug against the human monkeypox virus in vitro at nanomolar concentrations. Thus, presenting opportunities for market expansion of this segment.
Start-ups help in understanding the outlook of any market. Start-ups also have the potential to generate higher returns which directly benefits in the expansion of any market. This is because these are typically more efficient at converting inputs into outputs. These are more flexible and adaptable, able to shift quickly in response to changing market conditions. Some of the start-ups that will aid in the expansion of the monkeypox treatment market are:
The global Monkeypox treatment market is extremely competitive owing to the presence of a large number of players and innovative product offerings. Additionally, business expansion activities through partnerships and agreements are factors projected to further increase the competition. The major players in the market are: SIGA Technologies Inc., Chimerix, Inc, Bavarian Nordic, Sanofi SA, Emcure Pharmaceuticals, Jinan Jinda Pharmaceutical Chemistry Co., Ltd, Emergent Pharmaceuticals, Gilead Sciences, Inc., Hetero, Piramal Pharma Solutions
Some Recent Developments in the market are:
Key market players are concentrating on the adoption of inorganic growth strategies such as acquisition, partnerships and collaboration in order to improve their product portfolio. This is anticipated to drive the global monkeypox treatment market.
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 93.84 million |
Market Value in 2033 | US$ 249 million |
Growth Rate | CAGR of 10.25% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
The market is anticipated to reach a valuation of US$ 93.84 million in 2023.
Asia Pacific is anticipated to surge at a CAGR of 11% through 2033.
The monkeypox treatment market is expected to reach US$ 249 million in 2033.
The North America is anticipated to augment at a CAGR of 9.1% through 2023.
Surging healthcare expenditure to present a dollar opportunity for the industry players.
1. Executive Summary | Monkeypox Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 5.3.1. Prophylactic – Vaccines 5.3.2. Therapeutic 5.3.2.1. Tecovirimat 5.3.2.2. Brincidofovir 5.3.2.3. Cidofovir 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Injectable 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Retail Pharmacies 7.3.2. Hospital Pharmacies 7.3.3. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Treatment Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Type 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Type 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom (UK) 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Treatment Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Singapore 12.2.1.5. Thailand 12.2.1.6. Indonesia 12.2.1.7. Australia 12.2.1.8. New Zealand 12.2.1.9. Rest of Asia Pacific 12.2.2. By Treatment Type 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Treatment Type 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Treatment Type 14.1.2.2. By Route of Administration 14.1.2.3. By Distribution Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Treatment Type 14.2.2.2. By Route of Administration 14.2.2.3. By Distribution Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Treatment Type 14.3.2.2. By Route of Administration 14.3.2.3. By Distribution Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Treatment Type 14.4.2.2. By Route of Administration 14.4.2.3. By Distribution Channel 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Treatment Type 14.5.2.2. By Route of Administration 14.5.2.3. By Distribution Channel 14.6. UK 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Treatment Type 14.6.2.2. By Route of Administration 14.6.2.3. By Distribution Channel 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Treatment Type 14.7.2.2. By Route of Administration 14.7.2.3. By Distribution Channel 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Treatment Type 14.8.2.2. By Route of Administration 14.8.2.3. By Distribution Channel 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Treatment Type 14.9.2.2. By Route of Administration 14.9.2.3. By Distribution Channel 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Treatment Type 14.10.2.2. By Route of Administration 14.10.2.3. By Distribution Channel 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Treatment Type 14.11.2.2. By Route of Administration 14.11.2.3. By Distribution Channel 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Treatment Type 14.12.2.2. By Route of Administration 14.12.2.3. By Distribution Channel 14.13. Singapore 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Treatment Type 14.13.2.2. By Route of Administration 14.13.2.3. By Distribution Channel 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Treatment Type 14.14.2.2. By Route of Administration 14.14.2.3. By Distribution Channel 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Treatment Type 14.15.2.2. By Route of Administration 14.15.2.3. By Distribution Channel 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Treatment Type 14.16.2.2. By Route of Administration 14.16.2.3. By Distribution Channel 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Treatment Type 14.17.2.2. By Route of Administration 14.17.2.3. By Distribution Channel 14.18. GCC Countries 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Treatment Type 14.18.2.2. By Route of Administration 14.18.2.3. By Distribution Channel 14.19. South Africa 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By Treatment Type 14.19.2.2. By Route of Administration 14.19.2.3. By Distribution Channel 14.20. Israel 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By Treatment Type 14.20.2.2. By Route of Administration 14.20.2.3. By Distribution Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Treatment Type 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. SIGA Technologies Inc. 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Chimerix, Inc. 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Bavarian Nordic 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Sanofi SA 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Emcure Pharmaceuticals 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Jinan Jinda Pharmaceutical Chemistry Co., Ltd. 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Emergent Pharmaceuticals 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Gilead Sciences, Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Hetero 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Piramal Pharma Solutions 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: Asia Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 19: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 20: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 21: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 23: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 24: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 17: Global Market Attractiveness by Treatment Type, 2023 to 2033 Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033 Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 37: North America Market Attractiveness by Treatment Type, 2023 to 2033 Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 57: Latin America Market Attractiveness by Treatment Type, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 77: Europe Market Attractiveness by Treatment Type, 2023 to 2033 Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033 Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: Asia Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 82: Asia Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 83: Asia Pacific Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 97: Asia Pacific Market Attractiveness by Treatment Type, 2023 to 2033 Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033 Figure 99: Asia Pacific Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 101: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 102: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 103: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 104: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 109: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 110: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 111: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 112: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 113: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 114: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 115: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 116: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 117: MIDDLE EAST AND AFRICA Market Attractiveness by Treatment Type, 2023 to 2033 Figure 118: MIDDLE EAST AND AFRICA Market Attractiveness by Route of Administration, 2023 to 2033 Figure 119: MIDDLE EAST AND AFRICA Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 120: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports